亚盛医药-B股价涨超7%,配股筹14.93亿港元,新药利沙托克拉上市填补国内空白,全球商业化潜力大,有望成第二款获批的BCL-2抑制剂。
Source Link亚盛医药-B股价涨超7%,配股筹14.93亿港元,新药利沙托克拉上市填补国内空白,全球商业化潜力大,有望成第二款获批的BCL-2抑制剂。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.